Fortress Biotech, Inc. (FBIO) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
	10-K	10-K	10-K	10-K/A	10-K	10-K	10-K	10-K
Revenue
Product revenue, net	71.0	63.1	44.5	34.9	23.4	15.5
Collaboration revenue	1.9	5.4

Revenue - related party
Net revenue	75.7	68.8	45.6	36.6	26.9	15.5	16.5	0.9
Net revenue growth	10.1%	50.9%	24.5%	36.3%	73.2%	-5.8%	1809.6%
Operating expenses
Research and development	134.2	113.2	61.3	6.1	87.4	48.3	35.1	29.8
Research and development - licenses acquired	0.7	15.6	2.8
Asset impairment, net
Loss from operations	-203.6	-188.5	-94.3	-110.8	-120.0	-89.8	-65.7	-50.5
Operating margin	-268.8%	-274.1%	-206.7%	-302.5%	-446.4%	-578.6%	-398.7%	-5855.3%

Other income (expense)
Interest income	1.4	0.6	1.5	2.6	1.1	0.8	0.3	0.2
Interest expense and financing fee	-13.6	-15.3	-15.3	-11.8	-10.3	-7.7	-3.7	-1.5
Change in fair value of warrant liabilities	1.1	-0.4	-1.2	0.0	-0.7	-0.4	-1.0	-0.4
Other income
Total other expense	-9.9	24.2	-8.6	9.2	-10.8	-7.7	-5.6	-3.4
Net loss	-213.9	-164.8	-103.0	-101.7	-141.9	-99.8	-71.3	-53.9
Net loss attributable to non-controlling interests	127.3	100.1	56.5	61.7	57.8	33.0	16.2	5.5
Net loss attributable to Fortress	-86.6	-64.7	-46.5	-40.0	-84.1	-66.9	-55.1	-48.4
Net loss attributable to common stockholders	-86.6	-64.7	-46.5	-40.0	-84.1	-66.9	-55.1	-48.4

Net loss per common share attributable to common stockholders - basic	($0.97)	($0.79)	($0.65)	($0.73)	($1.94)	($1.61)	($1.38)	($1.24)
Net loss per common share attributable to common stockholders - diluted	($0.97)	($0.79)	($0.65)	($0.73)	($1.94)	($1.61)	($1.38)	($1.24)

Weighted average common shares outstanding - basic	88.9	81.7	72.0	54.7	43.5	41.7	40.0	39.1